Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine.
Authors not listed
Medical University of Vienna · 2010
Abstract
The aim of this project is to investigate humoral and cellular immune responses before and after immunisation with the Japanese encephalitis vaccine IXIARO in subjects above 60 years of age and 18-40 years old subjects.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-25 MST
Cite this
APA
Anonymous. (2010). Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine. <em>Medical University of Vienna</em>. https://clinicaltrials.gov/study/NCT01398540
Vancouver
Anonymous. Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine. Medical University of Vienna. 2010.
BibTeX
@misc{anon2010Charac,
title = {Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine.},
author = {Anonymous},
journal = {Medical University of Vienna},
year = {2010},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Sanofi Pasteur, a Sanofi Company 2007
Open access · US-GOV
Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route
GlaxoSmithKline 2007
Open access · US-GOV
An Extension Study to Evaluate the Persistence of the Immune Responses Induced by GSK Biologicals Zoster Vaccine, GSK324332A, Administered in Healthy Adult Subjects Aged 18-30 Years and 50-70 Years
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2021
Open access · US-GOV
A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above
China National Biotec Group Company Limited 2021
Open access · US-GOV
A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged ≥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old
National Vaccine and Serum Institute, China 2022
Open access · US-GOV
A Randomized, Controlled Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) in Population Aged 18 Years and Above
University of Lausanne Hospitals 2013
Open access · US-GOV